---
title: "3 Best Cheap Stocks Under $10 to Buy Now, According to Analysts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288906591.md"
description: "Wall Street analysts highlight three undervalued stocks under $10 with strong upside potential: CytomX Therapeutics (CTMX), Dakota Gold (DC), and Camping World (CWH). CTMX, favored for its innovative cancer therapy platform and recent 'Buy' rating from Wolfe Research, shows a Strong Buy consensus with an average price target of $12.30, implying 310% upside. The selection is driven by improving fundamentals, rising industry demand, and upcoming catalysts."
datetime: "2026-06-05T21:08:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288906591.md)
  - [en](https://longbridge.com/en/news/288906591.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288906591.md)
---

# 3 Best Cheap Stocks Under $10 to Buy Now, According to Analysts

Low‑priced stocks do not mean low potential. Several stocks under $10 are drawing attention from Wall Street analysts thanks to improving fundamentals, rising demand in their industries, and catalysts that could drive meaningful upside. Here are the three analyst‑favored cheap stocks that stand out right now: CytomX Therapeutics (CTMX), Dakota Gold (DC), and Camping World (CWH).

### Claim 55% Off TipRanks

-   Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
-   Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter

## **1\. CytomX Therapeutics (CTMX)**

CytomX is gaining momentum due to its progress in next‑gen cancer therapies. Its Probody platform, designed to activate cancer‑fighting drugs only inside tumors, has attracted partnerships with major pharma players and continues to advance through clinical milestones.

Last month, Wolfe Research analyst Kalpit Patel initiated coverage with a Buy rating. He said CytomX stock is undervalued because its drug Varseta‑M is showing strong response rates in late‑line colorectal cancer. He sees room to move the drug into earlier treatment lines and views the recent pullback as a buying chance ahead of several catalysts over the next year.

On TipRanks, analysts have a Strong Buy consensus rating on CytomX stock based on 10 Buys assigned in the past three months. Further, the average CTMX stock price target of $12.30 per share implies 310% upside potential.

### Related Stocks

- [CTMX.US](https://longbridge.com/en/quote/CTMX.US.md)
- [DC.US](https://longbridge.com/en/quote/DC.US.md)
- [CWH.US](https://longbridge.com/en/quote/CWH.US.md)
- [DC+.US](https://longbridge.com/en/quote/DC+.US.md)

## Related News & Research

- [KBC Group NV Acquires New Holdings in Camping World $CWH](https://longbridge.com/en/news/293817586.md)
- [Camping World (CWH) To Report Earnings Tomorrow: Here Is What To Expect](https://longbridge.com/en/news/294004717.md)
- [Calidi Biotherapeutics targets Q1 2027 clinic entry for CLD-401 cancer program](https://longbridge.com/en/news/293929420.md)
- [Dakota Gold posts investor-and-analyst tour deck on revitalizing South Dakota’s Homestake District](https://longbridge.com/en/news/293238789.md)
- [CytomX Therapeutics doubles authorized common shares to 600 million](https://longbridge.com/en/news/290478262.md)